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Available online xxxxPlatelets play a key role in the pathogenesis of ventricular assist device (VAD) thrombosis; therefore, antiplatelet
drugs are essential, both in the acute phase and in the long-term follow-up in VAD management. Aspirin is the
most used agent and still remains the ﬁrst-choice drug for lifelong administration after VAD implantation. Anti-
coagulant drugs are usually recommended, but with a wide range of efﬁcacy targets. Dual antiplatelet therapy,
targeting more than one pathway of platelet activation, has been used for patients developing a thrombotic
event, despite an increased risk of bleeding complications. Although different strategies have been attempted,
bleeding and thrombotic events remain frequent and there are no uniform strategies adopted for pharmacolog-
icalmanagement in the short andmid- or long-term follow up. The aim of this article is to provide an overview of
the evidence from randomized clinical trials and observational studies with a focus on the pathophysiologic
mechanisms underlying bleeding and thrombosis in VAD patients and the best antithrombotic regimens
available.
© 2018 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Depending on the deﬁnition applied, the prevalence of heart failure
(HF) is approximately 1–3% in the adult population, rising to 8–10% for
subjects aged 75 years or older [1, 2]. In patients acutely hospitalized, HF
is still associatedwith very poormedium-termprognosis,with all-cause
death being approximately 20% and all-cause re-hospitalization rate up
to 50% at 1-year follow up [3].
Permanent implantable ventricular assist devices (VADs) are a
consolidated alternative to heart transplantation (HTx) for ineligible
patients with end-stage HF (destination therapy). VADs are currently
implanted also in patients on waiting list for HTx (as bridge to trans-
plantation) or needing evaluation for candidacy in order to achieve
end-organ recovery (bridge to candidacy) [1].e reliability and freedom from
ion.
o-vascolare, Intensive Coronary
nde Ospedale Metropolitano
.
. Morici).
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only. No other uses without permissVADs can be categorized based on their mechanism of blood propul-
sion. First generation VADs were pulsatile devices mimicking the natu-
ral heart ﬂow dynamic, whereas second- and third-generation devices
provide continuous ﬂow (with axial or centrifugal design) [4].
Despite technological improvements (greater durability and easier
placement)with the continuousﬂowdesign, bleeding and thromboem-
bolism, aswell as pump thrombosis, remain frequent complications that
may affect the long-term outcome of patients on VAD [5–7]. Indeed,
only 30% of patients remain free from bleeding or thromboembolic
complications after 1 year from VAD implantation [8].
The event rate per patient-year is ≈0.40 and 0.06 for non-
gastrointestinal and gastrointestinal major bleeding [9], 0.04 to 0.09
for pump thrombosis [10], and 0.08 for hemorrhagic or ischemic stroke
[9]. The clinical consequences of thrombotic and bleeding complications
can be devastating, with ischemic and hemorrhagic stroke remaining
among the most common causes of death in these patients (adjusted
hazard ratio 6.1; 95% CI, 4.6–7.9) [11]. Even if an increase in pump
thrombosis reported in previous studies [12–14] has been mitigated in
recently published trials [15, 16], pump thrombosis may be a vexing
problem because of older patients and longer duration of life after im-
plantation. Device manufacturers usually suggest the use of a speciﬁc
antiplatelet or anticoagulant agent, without any strong evidenceC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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in patients with VADs is still evolving to better face the ﬁne balance
between bleeding and thrombosis.
The aimof the present review is to summarize the available evidence
about the pathophysiological mechanisms contributing to bleeding and
thrombosis in VAD patients, themanagements that are usually adopted
and the future lines of research.
2. Search strategy
Databases including PubMed, OVID, SCOPUS, CINAHL, Cochrane
and Web of Science were searched from database inception through
to 28 March 2018, using the predeﬁned search terms “assist device”,
“thrombosis”, “bleeding”, “antiplatelet therapy”, “anticoagulation”,
“antithrombotic management” using Boolean logic operators (AND)
and (OR), with exploded headings. Search of the literature was
performed without predeﬁned “timeframe” for published articles. No
language and study type limits were applied. Reference lists of selected
publications were also analyzed for additional linking studies.
3. Pathophysiology of thrombosis and bleeding in LVAD patients
Thrombus formation is a dynamic process that is regulated by com-
ponents of the hemostatic system, which, under physiological condi-
tions, form blood clots that limit blood loss from damaged vessels
[15]. Platelet reactions with the solid surfaces of damaged blood vessels
depend on the presence of plasma vonWillebrand Factor (vWF) activity
[17]. vWF is amultimeric glycoproteinmanufactured by the endothelial
cells, where it is constitutively released into the circulation and stored
into the Weibel-Palade bodies, from where it can be rapidly released
upon stimulation [17, 18]. vFW is stored also in theα-granules ofmega-
karyocytes/platelets, fromwhich it is released only upon platelet activa-
tion [17, 18]. vWF circulates in the plasma and it is critical for primary
hemostasis, being essential for platelet adhesion to the subendothelium
of damaged blood vessel, platelet activation and platelet aggregation
[19]. Furthermore, it is required to control the formation of vascular net-
work [19].
Rheological variables play a role in thrombus formation, by affecting
the ability of platelets to hook up to adhesive proteins that are exposed
on the vessel wall (platelet adhesion) or are bound on the surface of
other platelets (platelet aggregation) [17]. Shear stress is deﬁned as
the force for area unit between the blood laminae. The normal physio-
logic range of ﬂuid shear stress within the cardiovascular system is 15
to 40 dyne/cm2 (1.5–4 Pa) [20]. Under physiologic shear stress, vWF
undergoes a conformational elongation from a globular state to an
extended chain conformation with exposure of binding sites for the
platelet glycoprotein complex GpIb/IX/V and various subendothelial
constituents [21]. The interaction of vWFwith platelet GPIb/IX/V causes
platelet activation, secretion of ADP, activation of the GpIIb-IIIa receptor
and platelet aggregation. However, the same conformation elongation
exposes the disulﬁde bonds of vWFmultimers, site of enzymatic degra-
dation cleavage of large, active vWF multimers into small, nonactive
vWF fragments by the vWF protease ADAMTS-13 (a disintegrin and
metalloproteinase with a thrombospondin type 1 motif, member 13)
[22–25]. Therefore, the pathogenesis of bleeding and thrombosis
depends on the imbalance between these pro-hemostatic and anti-
hemostatic factors.
3.1. Thrombosis
Each VAD has a speciﬁc mechanism of blood propulsion, able to pro-
duce different hemodynamic proﬁles associated with changing degrees
of pulsatility, turbulence and shear stress. The shear stress that is gener-
ated within VADs ranges between 20 and 500 Pa [26, 27].
Shear stress acts as chemical agonists, showing dose and time-
response characteristics. The elongated vWF formed under conditionsDownloaded for Anonymous User (n/a) at SBBL- Hospital Nigu
For personal use only. No other uses without permission. Cof high shear stress becomes procoagulant through accumulation of
contact pathway factors. Accordingly, placement of VADs has been asso-
ciatedwith persistent generation of activated contact proteins (FXIa and
its co-localized activator FXIIa), that accumulate on the vWF as they
form under pathological ﬂow [28] and are absorbed to the surface of
VADs via the Vroman effect (according to the original theory, the small
molecules are the ﬁrst to be absorbed on a surface, but they are gradu-
ally stiﬂed by proteinswith greater afﬁnity) [29]. The threshold evoking
a speciﬁc response in terms of platelet adhesion and aggregation may
change over time depending on the speciﬁc interactions between plate-
lets and solid surface and the exposition time [17].
Platelet aggregation induced under supraphysiologic shear stress, as
usually occurred in patients with VAD, has peculiar characteristics
[30–33]. Thrombelastographic analyses have demonstrated that contact
protein pathway activation results in a thrombus that develops strength
at a signiﬁcantly faster rate and that takes signiﬁcantly longer to lyse
than thrombi generated by tissue factor initiated coagulation, by more
efﬁcient activation of the thrombin-activatable ﬁbrinolysis inhibitor
[34]. It is well known that vWF stress-stimulated aggregation is little
affected by inhibition of cycloxygenase by acetylsalicylic acid, whereas
it is inhibited by ﬁbrinolytic agents [35,36].Therefore, ideally, agents
acting on ADP activity (as P2Y12 inhibitors), blocking GP Ib or GP IIb/
IIIa or acting on the ﬁbrinolytic system might be suitable therapeutic
target to decrease thrombosis rate in VAD patients.
In experimental studies analyzing platelet-rich plasma under condi-
tions of high shear stress, N50% of activation and aggregation caused by
the interaction of vWFwith platelet GP Ib could be inhibited by blocking
the action of P2Y12 [37].
Similarly, studies in vitro have demonstrated that, under
supraphysiologic shear stress, phosphodiesterase (PDE) 3 inhibitors
suppress the platelet thrombus formation initiated by the interaction
of the platelet receptor GPIb/V/IX with the vWF [38]. The only selective
PDE-3 inhibitor available is cilostazol. Several observations conducted
in vitro have conﬁrmed the favorable proﬁle of cilostazol in reducing
platelet activation under both constant and dynamic device-related
conditions [33, 39, 40]. However, as recently reported, FDA has contra-
indicated the use of cilostazol for patients with any degree of heart
failure [33, 41]. Dipyridamole is both a PDE-3 and -5 inhibitor, but
studies in vitro have revealed its decreased activity on platelet inhibi-
tion under conditions of high shear stress [33].
Finally, a further mechanism leading to thromboembolic complica-
tions in VAD patients could be the heat stress. Investigations in this
ﬁeld have revealed hemoconcentration, activation of coagulation with
decreased clotting time and increased clot strength and thrombin and
D-dimer release [42]. Heat stress may act promoting activation of
several inﬂammatory pathways and inducing the release of chemical
agonists as epinephrine. This explains why in this context inhibition
of the cyclo-oxygenase enzymes by acetylsalicylic acid, decreasing
production of prostaglandins and other inﬂammatory mediators, is of
potential beneﬁt [43].3.2. Bleeding
On the opposite site of the coin, shear stressmay have a role in bleed-
ing diathesis. Acting on the weaker disulﬁde bonds of vWF multimers,
shear stress could tear apart vWFmonomers. In parallel, supraphysiologic
shear stress is the major mechanism leading to enzymatic degradation
cleavage of large, active vWF multimers into small, nonactive vWF frag-
ments by the vWF protease ADAMTS-13 (a disintegrin and metallopro-
teinase with a thrombospondin type 1 motif, member 13) [30]. As a
result, an acquired vWF deﬁciency develops, thus signiﬁcantly affecting
sprouting angiogenesis. vWF is a ligand for the integrin αvβ3, involved
in the regulation of the directionality of cellular migration [22]. Further-
more, vWF drives the formation of Weibel-Palade bodies, which stores
regulators of angiogenesis and inﬂammation including angiopoietin-2.arda from ClinicalKey.com by Elsevier on July 30, 2018.
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tion of αvβ3 and increased release of angiopoietin-2 [22–25]. Dysregu-
lated angiopoietin-2 may lead to endothelial cells proliferation and
migration throughout the vascular endothelial growth factor (VEGFR)-
dependent pathways, with increased neo-angiogenesis and vasculariza-
tion [18, 22–25, 44].
Increased angiopoietin-2 release further induces αvβ3 internaliza-
tion, amplifying cellular proliferation and migration [25]. These multiple
cross-talking pathways results in dysplastic vessels and arterio-venous
malformations predisposing patientswith a VAD to bleeding events [45].
Moreover, diminished pulsatility and increased intraluminal pressure
have also been postulated to induce distention of submucosal venous
plexus and microvascular perfusion injury of the small bowel [45].
Finally, patients with blood type O have been noted to have lower
baseline levels of vWF compared with other blood groups, though the
precise mechanism of this regulation remains unknown [46]. However,
these slight differences are unlikely to be clinically signiﬁcant, as
reported in studies performed in patients undergoing coronary artery
bypass [46]. Moreover, in patients with centrifugal devices, the vWF
antigen and vWF activity did not differ among individuals with blood
group “O” compared to the other blood groups [47].
These complex relationships (Fig. 1) acknowledge why it is so
difﬁcult to ﬁnd a proper management in patients with VAD support.
Summarizing the available evidences fromprior publishedwork is chal-
lenging because different pumps and center-speciﬁc protocols have
been adopted, limiting our ability to deﬁnitively integrate the available
information. Finally, it should always be taken into consideration that
risk factors contributing to pump thrombosis are related not only to
the pump itself, but even to the patient pre-existing conditions (atrial
ﬁbrillation, preexistent thrombus, uncontrolled hypertension, hyperco-
agulable state as in course of anti-phospholipid antibody syndrome,
acute heparin-induced thrombocytopenia or active infection) and
patient's compliance with regular medications drugs [48].
4. Antithrombotic strategies
4.1. Secondary prevention of thromboembolic events after VAD implantation:
anticoagulant treatment
According to the International Society of Heart and Lung Transplan-
tation guidelines [49] supported by the American Heart Association
[50], patients with VAD should receive anti-coagulation with warfarin
to maintain an International Normalized Ratio (INR) within a range as
speciﬁed by each device manufacturer; aspirin (81–325 mg daily) and
other antiplatelet drugs may be used in addition to warfarin according
to the recommendations of speciﬁc device manufacturers, but these
indications are mostly based on experts' opinion [49, 50].
Table 1 summarizes the most commonly implanted devices, their
speciﬁc rheology and the recommended antithrombotic regimen by
each device manufacture.
In the 2012 Rossi et al. published a review including 538 patients
with axial-ﬂow VAD (HeartMate II, Jarvik 2000, INCOR, Thoratec assist
device). Search strategies involved 758 papers retrieved from 1950 to
March 2012. Pooling the results of the 17 papers included in the ﬁnal
analysis, the authors suggested that use of warfarin (INR target 2.5),
in association with aspirin at 100 mg/day could be considered the best
option [51].
In 2015, Bauman et al. published a systematic review focused on
the antithrombotic therapy for left ventricular assist devices (LVADs),
both axial and centrifugal, in adults [52]. The authors screened 1276
articles identiﬁed throughout database searching and other sources.
One-hundred and four articles were assessed for eligibility and 24
studies were included in the qualitative synthesis, reporting outcomes
of 2784 LVADs with a range of implantation time between 1 day and
2823 days. Almost all of the studies were deemed of moderate quality,
as they were mostly retrospective and without a comparison group.Downloaded for Anonymous User (n/a) at SBBL- Hospital N
For personal use only. No other uses without permissioThe different antithrombotic strategies adopted and the lack of a stan-
dardized deﬁnition of bleeding between studies limited the ability to
compare antithrombotic regimens. Major bleeding, according to each
study deﬁnition, was reported in 30% of patients. Stroke and pump
thrombosis were reported in 6% and 5% of patients. Death was reported
in 20% of patients. The most frequent causes of death were multiorgan
failure (31%), infections (15%), ischemic stroke (13%), right heart failure
(11%), bleeding (10%), mechanical failure of the device (3%), with fatal
bleedings and fatal thromboembolic complications showing similar
incidences. The authors concluded that lack of effective INR control
may be associated with bleeding and thromboembolic complications
and that the optimal antithrombotic regimen in LVAD patients remains
undetermined. Moreover, the role of antiplatelet therapy during LVAD
support was still unclear.
The most recent evidences of the current literature show that
differences in markers of hemolysis and coagulation activation
may exist according to the speciﬁc VAD implanted [14–16, 53].
Actually, the improved hemocompatibility achieved with the new
generation devices has led to the conclusion that low-intensity
anticoagulation (INR range 1.5–1.9) could be a safe and effective
strategy in patients closely monitored with new magnetically levi-
tated centrifugal-ﬂow circulatory pump, associated with a short
term (six weeks post-implantation) antiplatelet strategy [14, 15, 54].
However, further studies on larger samples are needed to conﬁrm this
hypothesis.
4.2. Secondary prevention of thromboembolic events after VAD implantation:
antiplatelet treatment
Even if aspirin is commonly recommended and used as the ﬁrst-
line therapy in patients with LVAD since the ﬁrst clinical experiences
[55], mechanisms of platelet activation in VADs patients (shear-
induced platelet aggregation) make the efﬁcacy of aspirin question-
able. Furthermore, an experimental study conducted in a small
sample of patients with external VAD implantation [56], has docu-
mented a non-trivial risk of aspirin hyporesponsiveness, deﬁned by
persistent platelet aggregation in 26% of the patients under arachi-
donic acid exposition. In this study patients on VADs support experi-
enced a persistent inﬂammatory status as expressed by elevated
ﬁbrinogen levels and circulating von Willebrand Factor values.
Mechanisms for aspirin hyporesponsiveness are potentially multiple
in VAD patients [17, 57–60]: a) an increase in platelets turnover may
overcome the effect of aspirin on thromboxane A2 synthesis [57];
b) chronic inﬂammatory status may promote the cyclooxygenase-2
isoform activity, that is less sensible to aspirin acetylation [58];
c) platelet adhesion and activation under high shear stress are poorly
sensitive to aspirin [59].
Clopidogrel has been suggested in the case of aspirin intolerance
[10] or according to speciﬁc indications, mostly in the context of recent
thromboembolic events [61]. However, the antiplatelet response to
clopidogrel, performed with the platelet function analyzer-100 system
and the vasodilator-stimulated phosphoprotein phosphorylation assay,
is highly variable, with almost 50% of patients showing insufﬁcient
anti-platelet response [53].
The combination of dipyridamole and aspirin is associated with a
decreased relative and absolute risk of thromboembolic events in VAD
patients of 50% and 9%. However, these data have been reported only
in few experiences with axial devices [54] and are inconsistent in the
general VAD population.
Prasugrel and ticagrelor, P2Y12 antagonists with more predictable
pharmacokinetics than clopidogrel, have not been routinely prescribed
in patients with VAD likely for fear of an inacceptable high risk of bleed-
ing events. One small case-series suggested a positive role of ticagrelor
in patients with suspected LVADs thrombosis [62]. However, on the
basis of our clinical experience, the generalizability of these optimistic
results is questionable [63].iguarda from ClinicalKey.com by Elsevier on July 30, 2018.
n. Copyright ©2018. Elsevier Inc. All rights reserved.
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Fig. 1. Thrombosis and bleeding pathways in patients with ventricular assist device. Under physiologic shear stress, vWF undergoes a conformational elongation from a globular
state to an extended chain conformation with exposure of binding sites for the platelet glycoprotein complex GpIb/IX/V and various subendothelial constituents. This interaction
causes platelet activation, secretion of ADP, activation of the GpIIb-IIIa receptor and platelet aggregation (central box and box on the top left). However, the same conformation
elongation exposes the disulﬁde bonds of vWF multimers and allows the inactivation process by the vWF protease ADAMTS-13 (box on the top right). Placement of VADs may
amplify these processes, increasing shear stress and promoting activated contact proteins release. Therefore, the increased activation of vWF may explain the dual pathway
activation: increased thrombosis by platelets activation and contact proteins system (pathway on the left) and bleeding diathesis throughout ADAMTS-13 activation and
acquired vWF disease (pathway on the right).
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Table 1
Ventricular assist devices usually implanted in our center and antithrombotic strategies suggested for secondary prevention of thromboembolic events.
Device Weight Type of ﬂow Range Speed Material motor can Material inﬂow canula Dose aspirin Range OAC (INR)
HM II 281 g Axial 8000–15,000 Titanium Titanium 100 mg 2–3
HM III 180 g Centrifugal 4000–9000 Titanium Titanium 100 mg 2–3
HW 160 g Centrifugal 2400–3200 Titanium Titanium 300 mg 2,5–3
HM: HeartMate, Thoratec Corporation; HW: HeartWare ventricular assist device system, HeartWare.
24 N. Morici et al. / IJC Heart & Vasculature 20 (2018) 20–264.3. Antithrombotic therapy in patients with thromboembolic events
Thrombolysis has been evaluated in patients with pump thrombosis
according to local algorithms based on single-center experiences.
However, a systematic review and metaanalysis has not documented
a signiﬁcant increased rate of success in patients with pump thrombosis
treated with thrombolytic regimens compared to nonthrombolytic
pharmacological management [64]. An extensive review of this issue
is out of the present revision.
Glycoprotein IIb/IIIa inhibitors have been evaluated as an alterna-
tive to ﬁbrinolysis in patients with suspected device thrombosis.
However, patients with conﬁrmed events, failed to have a clinically
measurable response to therapy [65, 66].
Direct thrombin inhibitors (DTI) might have a strong rationale in
this setting.
Bivalirudin is a speciﬁc and reversible DTI used in clinical practice
since the early '90s, as an alternative medication to heparin, during
percutaneous coronary intervention (PCI) [67]. DTIs are better pharma-
cological tools, compared to unfractionated heparin (UFH). Their advan-
tages include being independent of antithrombin III levels, better
bioavailability, and capacity to inhibit both soluble and clot-bound
thrombin, which reduces clot formation and propagation. Furthermore,
DTIs inhibit thrombin-induced platelet activation [68].
About 20% of bivalirudin is excreted unchanged in the urine. Drug
elimination depends on glomerular ﬁltration rate; therefore, the half-
life is 25–30 min in healthy patients but is increased to 1 h in severe
renal disease and is estimated to be 3.5 h in end-stage renal disease
requiring hemodialysis. Intravenous administration of bivalirudin pro-
duces measurable anticoagulation within few minutes with linear
increases in prothrombin time, activated partial thromboplastin time
(aPTT), activated clotting time (ACT) and thrombin time [68].
Bivalirudin has been approved for use in patients undergoing PCI
with or without prior treatment with unfractionated heparin (UFH)
and in patients with heparin-induced thrombocytopenia (HIT) and cur-
rent guidelines support its use in acute coronary syndrome patients
[69]. In patients undergoing PCI, it is administered as a bolus of
0.75 mg/kg, followed by a continuous infusion at 1.75 mg/kg/h for the
entire procedure. The infusion dose should be reduced in patients
with renal insufﬁciency: 1 mg/kg/h for patients with creatinine clear-
ance b30 ml/min, and 0.25 mg/kg/h for patients in hemodialysis [70].
Mueller et al. reported the successful use of bivalirudin therapy for
prevention of hemoﬁlter occlusion during continuous veno-venous
hemoﬁltration (CVVH) in a patient with hepatic and renal dysfunction.
The bivalirudin dosewas 0.09mg/kg/h. No bleeding complicationswere
noted [71].
Preliminary experiences in patients with VAD implantation have
been favorable. In 2014 Pieri et al. performed a study on 12 consecutive
patients who underwent VAD implantation and received primary
anticoagulation with Bivalirudin: the starting dose was 0.025 mg/kg/h,
the median dose was 0.04 ± 0.026 mg/kg/h and median duration of
therapy was 5 days. Patients never received heparin during hospitaliza-
tion nor had a prior diagnosis of HIT. No patient had thromboembolic
complications or major bleeding events and the authors concluded
that bivalirudin should be a valuable alternative anticoagulant therapy
in VAD patients. Other clinical experiences have conﬁrmed the safety
proﬁle in this setting [72].Downloaded for Anonymous User (n/a) at SBBL- Hospital N
For personal use only. No other uses without permissioEvidences to support the use of a DTIs in LVAD aremostly anecdotal.
In the small case series reported by Lynne et al. bivalirudin was used as
an alternative to heparin in six hemodynamically stable patients admit-
ted to hospital for suspected LVAD thrombosis. The starting dose was
between 0.03 and 0.15 mg/kg/h and the maintenance dose ranged
from 0.04 to 0.23 mg/kg/h. In these cases, bivalirudin was relatively
safe and effective for the treatment of LVAD thrombosis even if a high
rate of recurrence was showed [73].
Argatroban is another intravenous DTI used in cases of suspected
LVAD thrombosis. It is metabolized by the liver, while it has no
renal clearance. In comparison with bivalirudin, argatroban has higher
afﬁnity for thrombin with a more effective inhibition of clot-bound
thrombin: the dose usually employed is 2 μg/kg/min, aiming at
prolonging aPTT to 1.5–3 times the baseline values. Argatroban also
prolongs the PT, thus interfering with laboratory monitoring of
warfarin, when the two drugs are co-administered [74].
Dabigatran, an oral DTI, have been evaluated in LVAD patients with
promising results [75]. However, a recent randomized controlled trial
showed an excess of thromboembolic events in dabigatran-treated
patients compared to phenprocoumon-treated patients [76].
Even if the dual pathway therapy with direct oral anticoagulant
agents combined with P2Y12 inhibitor appears promising in patients
with acute coronary syndromes, based on the results of recent random-
ized trials on dabigatran and rivaroxaban [77, 78], this strategy has not
been tested in LVAD patients. Moreover, in view of the unfavorable
results in patients with mechanical valves, this option deserves ad hoc
well-designed trial.
In our clinical experience all the pharmacological strategies above
reported have been attempted in different clinical scenarios. Bivalirudin
has been used with a good proﬁle of safety and efﬁcacy in patients at
higher risk for both the conditions (suspected pump thrombosis and
hemorrhagic events, even cerebral hemorrhagic foci).
5. Conclusions
Antithrombotic management in VADs patients is based on ancient
protocols without strong experimental evidence. Large clinical trials
with standardized laboratory methods and well-deﬁned protocols are
needed in order to evaluate the different antiplatelet and anticoagulant
drugs available, suggesting therapeutic strategies to overcome the risk
of thrombotic and bleeding events.
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